Table 1. The PI3K/AKT and JAK/STAT pathways are vital to the proliferation of ALCL cells.
| Karpas 299 | Michel | SUDHL-1 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Kinase Inhibitor | G1 | S | G2/M | G1 | S | G2/M | G1 | S | G2/M |
| DMSO | 33.8 ± 6.3 | 50.6 ± 7.4 | 12.4 ± 1.8 | 28.9 ± 5.9 | 54.1 ± 5.0 | 14.0 ± 3.0 | 26.3 ± 4.0 | 52.5 ± 2.1 | 19.4 ± 3.7 |
| PI3K (LY290042) | 74.1 ± 1.9* | 13.5 ± 1.2 | 7.3 ± 1.3 | 63.1 ± 5.8* | 20.1 ± 2.3 | 11.6 ± 2.8 | 45.0 ± 5.2* | 33.4 ± 2.3 | 17.9 ± 2.3 |
| PI3K (Wortmannin) | 51.2 ± 8.2* | 40.2 ± 8.4 | 5.2 ± 0.43 | 53.4 ± 8.7* | 34.7 ± 6.4 | 7.5 ± 1.7 | 48.6 ± 1.6* | 34.3 ± 0.65 | 14.3 ± 1.0 |
| mTOR (Rapamycin) | 64.5 ± 5.1* | 24.7 ± 4.4 | 6.9 ± 1.0 | 55.7 ± 7.0* | 30.2 ± 3.7 | 9.8 ± 2.6 | 37.4 ± 1.2* | 44.7 ± 1.6 | 15.4 ± 1.9 |
| JAK (WHI-P131) | 67.2 ± 5.0* | 24.9 ± 4.5 | 5.3 ± 0.7 | 60.4 ± 14.1* | 30.6 ± 10.1 | 6.2 ± 2.9 | 46.3 ± 2.9* | 40.4 ± 2.0 | 9.6 ± 1.4 |
| JNK (JNK II) | 52.1 ± 1.7 | 27.3 ± 8.4 | 16.3 ± 7.5 | 21.5 ± 4.4 | 35.1 ± 5.8 | 37.1 ± 6.5 | 3.9 ± 1.8 | 16.7 ± 1.0 | 68.9 ± 2.7 |
| JNK (SP600125) | 51.9 ± 3.5 | 29.5 ± 5.7 | 14.2 ± 5.1 | 24.9 ± 2.2 | 36.1 ± 6.0 | 32.9 ± 5.4 | 4.0 ± 2.0 | 16.4 ± 1.2 | 71.6 ± 2.3 |
| ERK (PD98059) | 35 ± 3.3 | 52.2 ± 4.5 | 9.5 ± 1.1 | 28.4 ± 5.7 | 54.1 ± 5.4 | 13.7 ± 1.0 | 26.7 ± 0.87 | 51.5 ± 1.4 | 18.9 ± 4.3 |
| p38 (SB203580) | 28.3 ± 5.0 | 54.5 ± 8.0 | 12.9 ± 3.2 | 24.0 ± 6.4 | 61.4 ± 6.4 | 10.4 ± 0.9 | 21.7 ± 1.8 | 61.1 ± 1.1 | 14.0 ± 1.2 |
Karpas 299, Michel, and SUDHL-1 cells were treated with the indicated kinase inhibitor and 24 h later were stained with propidium iodide to visualize cell cycle profiles. *P < 0.001.